This paper was written by Dr. Mikuriya in October ’99 with O’Shaughnessy’s in mind; but then I went to work for the San Francisco District Attorney’s office and we put off the launch of the paper. It was never published. Given the title he chose, I’ve moved the concluding section to the beginning (which is why the footnotes are out of order). —Fred Gardner
American Drug Policy, Dependencies, and Cannabis
The complex interplay of cannabis use with physiology, psychology, and groups challenges research. Outcomes are combination of pharmacology, expectations, setting, personal and social forces. The contemporary ambiguity, a product of ignorance from deprivation of contemporary clinical experience, may be somewhat assuaged by two facts: Firstly, cannabis has been used for millennia by numerous cultures without serious adverse consequences.xxii Secondly, neither the composition of cannabis nor the physiology of humans have changed since the drug was taken from the armementarium of medicine.
Perceptions of cannabis and its effects distorted by sixty years of prohibition are embedded in official policyxxiii. The Controlled Substances Act of 1970xxiv classifies cannabis as Schedule I: high potential for abuse, no currently accepted medical use, and lack of accepted safety. The 1999 Institute of Medicine report favorably compares the psychophysical profile of cannabis to other conventional medication in chronic pain and spastic conditions but avoids any recommendation of using cannabis for the treatment of alcohol and drug dependencies.xxv
To circumvent prohibition censorship and dissimulation of contemporary official propaganda a review of medical and pharmaceutical literature prior to the passage of the Marihuana Tax Act in 1937 is mandatory. Cannabis was available and utilized extensively in medical practice until its removal from availability. There was an overall decline in its use with the development of newer synthetic sedative, stimulant, and analgesic drugs.
Criminalization of dependencies in the United States began in 1869 when the Temperance party became the Prohibition party. The ensuing state-by-state war of the drys against the wets culminated in national victory in 1919 with the passage of the Voalstead Act with Prohibition of alcohol.
The Harrison Narcotics Act of 1914 criminalized non medical use of opiates and cocaine. In 1921 the Federal Prohibition Commissioner criminalized the maintenance of unconfined narcotic addicts.xxvi The subsequent demonization and persecution of physicians and narcotic addicts they sought to treat significantly limited treatmentxxvii. Methadone maintenance programs available since the 1970’s remain heavily bureaucratized and functionally rationed. Alcohol and drug dependency treatment remain frequently unavailable. The last to be funded, first to be cut from public budgets and often not covered by private insurance. In America drug policy is controlled by the Attorney General —not the Surgeon General. Drug dependencies are defined as moral defects and not medical problems. Police become the armed pharmacologists. DARE (“Drug Awareness and Resistance Education”) celebrated its 17th birthday with uniformed police in the class rooms.
Meanwhile, television and print media tell us to ask your physician about Paxil® (paroxetine), an SSRI antidepressant.
O’Shaughnessyi in 1839 visited cannabis buyers centers in India and mingled with the “dissolute and depraved” to learn about the preparations of this social drug for clinical medical trials finding it to be useful in the treatment of tetanus and seizures.
Cannabis substitution for more harmful medicines
In 1843 Clendinningii utilized cannabis substitution for the treatment of alcoholism and opium addiction. Potter recommended full dose Squibb cannabis extract for withdrawal from opium addictioniii.
The Indian Hemp Drugs Commission Report in 1894 recognized the comparative safety of cannabis in its unsurpassed ethnographic studies within different cultures with a concern that if prohibited would cause the use of more dangerous drugs.iv
Cannabis combination with other medicines: decrease of dose, suppression of side effects
Mc Meens citing Fronmueller in 1860v described the use of cannabis either alternating or combined with opiates reduced harm from increased dose, tolerance, dependence, and side effects. Cannabis was confirmed as useful in the treatment of delirium tremens and alternative to opium for analgesiavi. Dutt independently described the comparative safety in Materia Medica of the Hindusvii. Yeo warned about addiction to morphine in the treatment of neuralgia and cannabis suggested as an alternative.viii
Cannabis and mood disorders
The connection between dependency on drugs and mood disorders may represent unsuccessful attempts to self medicate uncomfortable feelings with the “cure” causing more harm and aggravation of the underlying condition.
Moreau described cannabis as being useful in the treatment of depression in 1845.ix
The drug is listed in medical texts and pharmaceutical catalogs for treatment of melancholia or mania.x xi xii xiii
Patients report that cannabis facilitate both anti mania and antidepressant medications. Cannabis used in combination with antidepressants appears to decrease the side effects of nervousness, muscle tension, and nausea for SSRI type antidepressants. Other patients report that cannabis is complementary. A typical report is that the SSRI elevates mood overall and cannabis improves affectual responsivity. Cannabis can either diminish the dosage needs for sufferers of bipolar disorders or substitute altogether for antimania medications. With symptoms of mania or agitation cannabis appears to decrease affectual lability.
Cannabis substitution for more harmful non-medical drugs
Notwithstanding some polysubstance abusers who maladaptively combine cannabis with other psychoactives, there appears to be a significant number of persons who have learned that cannabis can totally substituted.
Following the therapeutic paths of Clendinning, throughout the 19th and early 20th century, cannabis was found useful in the treatment of opiate and sedative abuse. Brunton describes use of cannabis for the treatment of opiate dependence or as a substitute when opiates were not tolerated.xiv Shoemaker finds in some instances cannabis to be used for the cure of opium or chloral habit.xv Birch xviadvocated for the use of Indian Hemp in the treatment of chronic chloral and opium poisoning. Mattison, an early addiction specialist, reccommended cannabis in as a substitute of morphine and cautioned his fellow physicians about hypodermic use of the drug. xvii
Alcohol abuse, stimulant, sedative, and opiod abuse and dependence are conditions potentially treatable with cannabis substitution. All of these conditions involve management of mood and emotional reactivity. While there have been numerous synthetic homologs developed, short acting psychotropic continue to have high potential for dependency and abuse. The quality of immediacy for mood management would appear to be inseparable from abuse potential but cannabis appears to be the exception because of lesser or milder withdrawal symptoms.
This may be accounted for by the lipophillic water insolubility of the tetrahydrocannabinols that appears to act through the prostaglandins as eicosanoids, precursors whose structures are similar.xviii While largely unknown in specific details, appears to modulate the behavior of the CNS either directly, or through the adrenopituitary axis. Additionally, eicosanoid peripheral physical activity in specific organ systems like lung tissue has been demonstrated in animals.
California cannabis center members and patients in my private practicexix independently rediscovered and confirmed that cannabis as a safer substitute for prescribed and non medical psychoactive drugs in the control of depression, anger, and anxiety. Cannabis substitution may be a gateway drug back to sobriety and dealing with the underlying psychopathologic etiologies.
Gieringer summarized 2479 California cannabis users interviewed by the authorxx noted 5.5% (136) described that the use of cannabis to be less harmful than alcohol, opiate, and other for drug dependencies as primary presenting illness. This group of self medicators cannabis has found far fewer adverse effects than opioids, sedatives, and stimulants. This small percentage is for dependencies as primary grossly underreports dependencies in chronic pain conditions.
Antabuse® (disulfiram) and alcoholism
I have personally successfully treated two patients suffering severe alcoholism with a combination of disulfiram and cannabis substitution. This “carrot and stick” approach appears to address the needs of pharmacologic management of mood and avoids relapse with emotionally stressful events.xxi
Posttraumatic Stress Disorders: A specialized category of dependencies
Adult children of alcoholic families are doubly harmed by abuse and functional ignorance. Abuse by violence, sexual abuse or emotional absence by one or both parents is compounded by failure to provide coping skills to deal with normal feelings and pathologic role models. Alcoholism and polysubstance dependence is significant with destructive and symbiotic family involvements.
Vietnam veterans and other survivors of horrific experiences of adulthood suffer from living nightmares and flashbacks triggered by certain specific stimuli that cause overwhelming fight-flight reactions. Chronic depression with insomnia and fearfulness frequently incapacitate and isolate.
Both groups have come to realize that cannabis is less toxic or harmful than alcohol, opiods, and other psychotropics in their continuing struggles with indelible memories and their physiologic concomitants. Cannabis is used to relieve depression, decrease emotional overreactivity, and sleep deficit.
The alternative medical movement represents a populist rebellion against conventional medicine for treating chronic relapsing illness that include alcohol and other drug dependencies. Cannabis self medication has been discovered to be a viable alternative to treat these conditions that may enhance or substitute for conventional pharmacotherapy. —THM Berkeley, CA 10/6/99
i O’Shaughnessy WB On the Preparations of the Indian Hemp or Gunjah (Cannabis Indica) Their effects on the animal system in health and their utility in the treatment of tetanus and other convulsive diseases. Trans Med and Phys Soc Bengal 1838 – 1840 pp 421 – 461. Reprinted in Marijuana Medical Papers 1839-1972 465pp MediComp Press, Oakland pp 1- 30
ii Clendinning J Observations on the Medicinal Properties of the Cannabis Sativa of India Med Chir Trans London 26: 188-210 1843.
iii Potter SOL Handbook of Materia Medica, Pharmacy, and Therapeutics P Blakiston, Son & Co Phila. 1895 pp. 664-665
iv Indian Hemp Drugs Commission Report Ibid Chapt X Section 490 pp 194-196
v McMeens RR Ohio State Medical Committee on Cannabis Indica Transactions of the Fifteenth Annual Meeting of the Ohio State Medical Society June 12-14 pp 75 -100. Reprinted in Marijuana Medical Papers 1839-1972 pp 117 -140.
vi Royle, JF and Headland FW A Manual of Materia Medica and Therapeutics 5th Ed 1867 pp 639 – 643
vii Dutt UC Materia Medica of the Hindus Thacker, Spink & Co. Calcutta 1877 pp 235 – 241
viii Yeo IB, Crawfurd R and Buzzard EF A Manual of Medical Treatment or Clinical Therapeutics Vol II William Wood & Co. 1899 pp 320 – 321
ix Moreau JJ Hashish and Mental Illness Ed Peters H and Nahas GG Translated by Barnett GJ Raven Press NY 1973
x Lilly’s Bulletin No 18, P 1, 1892
xi Merck’s 1896 Index
xii Shoemaker JV Materia Medica and Therapeutics F A Davis Co Philadelphia 1906 p 305- 308.
xiii Dispensatory of the United States of America 20th Ed JB Lippincott Co. Philadelphia 1920 276 – 281
xiv Brunton TL A Text Book of Pharmacology, Therapeutics, and Materia Medica Lea Brothers & Co 1888 pp. 1026 – 1027
xv Shoemaker JV Materia Medica and Therapeutics FA Davis Co., Phila. 1906 pp. 305 -308
xvi Birch EA The Use of Indian Hemp in the Treatment of Chronic Chloral and Chronic Opium Poisoning. Lancet 1889: 1: March 30 Reprinted in Marijuana Medical Papers
xvii Mattison JB Cannabis as an Anodyne and Hypnotic St Louis Med and Surg J LXVI(5) Nov 1891. (Reprinted in Marijuana Medical Papers)
xviii Burstine S Eicosanoids as Mediators of Cannabinoid Action Ch 3 Marijuana/Cannabinoids Neurobiology and Neurophysiology Ed. Murphy L & Bartke A CRC Press Boca Raton 1992 pp. 73 – 91
xix Mikuriya TH Medical Uses in California www.mikuriya.com/ccua (abstract International Cannabinoid Research Society 1999 Symposium on the Cannabinoids June 18-20, 1999 Acapulco P.89
xx Gieringer D Medical Uses of Cannabis in California (in press)
xxi Mikuriya TH Cannabis Substitution as an Adjunctive Therapeutic Tactic in the Treatment of Alcoholism Medical Times 98:4 Apr 1970 pp. 187-191 Reprinted in Marijuana Medical Papers 1839 –1972 pp. 169-
xxii Indian Hemp Drugs Commission Report Vol 1 of 8 1894, Simla, Chapt X Effects – General Observations
xxiii McCaffrey BR Federal Response to California’s passage of Proposition 215 press conference and related documents 12-30-96.
xxiv Comprehensive Drug Abuse Prevention and Control Act of 1970 (Public Law 91-513)
xxv Joy JE et al Editors Marijuana and Medicine Assess the Science Base Institute of Medicine National Academy Press Washington DC 1999 267 pp.
xxvi Terry CE & Pellens M The Opium Problem 1928 Bureau of Social Hygiene New York 1928 (Reprinted Patterson Smith 1970) 1042 pp. P. 857
xxvii Williams HS Drug Addicts are Human Beings The Story of Our Billion Dollar Drug Racket How We Created It and How We Can Wipe It Out Shaw Publishing Co. Washington DC 1938 273 pp.